219 related articles for article (PubMed ID: 26983860)
1. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
Khan DD; Friberg LE; Nielsen EI
J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
Mohamed AF; Cars O; Friberg LE
J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
Dudhani RV; Turnidge JD; Coulthard K; Milne RW; Rayner CR; Li J; Nation RL
Antimicrob Agents Chemother; 2010 Mar; 54(3):1117-24. PubMed ID: 20028824
[TBL] [Abstract][Full Text] [Related]
4. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
[TBL] [Abstract][Full Text] [Related]
6. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
[TBL] [Abstract][Full Text] [Related]
8. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
Kristoffersson AN; David-Pierson P; Parrott NJ; Kuhlmann O; Lave T; Friberg LE; Nielsen EI
Pharm Res; 2016 May; 33(5):1115-25. PubMed ID: 26786016
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
Nielsen EI; Cars O; Friberg LE
Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.
Bergen PJ; Bulitta JB; Forrest A; Tsuji BT; Li J; Nation RL
Antimicrob Agents Chemother; 2010 Sep; 54(9):3783-9. PubMed ID: 20585118
[TBL] [Abstract][Full Text] [Related]
11. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
Dudhani RV; Turnidge JD; Nation RL; Li J
J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
[TBL] [Abstract][Full Text] [Related]
12. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints.
Tsala M; Vourli S; Georgiou PC; Pournaras S; Tsakris A; Daikos GL; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2018 Apr; 73(4):953-961. PubMed ID: 29377998
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
14. In vitro Pharmacodynamics and PK/PD in Animals.
Lee W; Cai Y; Lim TP; Teo J; Chua SC; Kwa AL
Adv Exp Med Biol; 2019; 1145():105-116. PubMed ID: 31364074
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.
Katsube T; Yano Y; Yamano Y; Munekage T; Kuroda N; Takano M
J Pharm Sci; 2008 Sep; 97(9):4108-17. PubMed ID: 18314887
[TBL] [Abstract][Full Text] [Related]
17. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Katsube T; Yamano Y; Yano Y
J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa.
Bozkurt-Guzel C; Gerceker AA
Indian J Med Microbiol; 2012; 30(1):34-8. PubMed ID: 22361758
[TBL] [Abstract][Full Text] [Related]
20. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
